Under one in 10 patients that would benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it publishes its first recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for increased and just availability to this class of drugs.
Based on projections, over two billion are projected to be obese by 2030 unless action is taken.
"Our new guidelines acknowledges that obesity is a chronic disease that can be managed with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key barriers to universal access to the jabs that can assist patients in reducing significant body mass, explains the organization.
GLP-1 Therapy Supply Crisis
Despite the current best projected case, the manufacturing of these medications could only cover about 100 million people – under 10% of those who need them, according to the health organization.
The recommendation urges nations and manufacturers to expand availability, via approaches such as voluntary licensing.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs mimick a body's own hormone to slow digestion, curb appetite and boost satiety so users consume fewer calories.
People usually start to lose weight after several weeks of commencing the regular doses.
Research points to patients may see weight return after a year of halting the treatment, as their normal hunger return.
To be overweight or obese raises your risk for contracting diseases, including diabetes, heart disease, brain attack, and some cancers.
Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
